Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis

作者：Wallace Mary C; Roberts Rebecca L; Nanavati Payal; Miner Jeffrey N; Dalbeth Nicola; Topless Ruth; Merriman Tony R; Stamp Lisa K^*

来源：Rheumatology, 2018, 57(4): 656-660.

DOI：10.1093/rheumatology/kex467

• gout
• allopurinol
• ABCG2

Objective. ABCG2 rs2231142 (Q141K) has been reported to be associated with poor response to allopurinol, while there are conflicting data on the association between the genetically independent ABCG2 rs10011796 variant and allopurinol response. The aim of this study was to replicate the association of ABCG2 rs2231142 and rs10011796 with allopurinol response and perform a meta-analysis.
Methods. Participants in the Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) (n = 299) were studied. In patients with evidence of adherence to allopurinol therapy (plasma oxypurinol > 20 mu mol/l), good response was defined as serum urate < 6 mg/dl on allopurinol <= 300 mg/day and poor response as serum urate 56 mg/dl despite allopurinol > 300 mg/day. Association of rs2231142 and rs10011796 with poor response was tested in logistic regression models that included age, sex, BMI, ethnicity and estimated glomerular filtration rate. Results from the LASSO study and a subset of participants in the Genetics of Gout in Aotearoa New Zealand study (n = 296, including 264 from a previously published report) were combined by meta-analysis.
Results. There was evidence for association of rs2231142 with allopurinol response [odds ratio (OR) = 2.35, P = 7.3 x 10(-4)] but not for rs10011796 (OR = 1.21, P = 0.33) in the LASSO cohort using an adjusted logistic regression model. Meta-analysis provided evidence of a significant association of rs2231142 with allopurinol response (OR = 2.43, P = 6.2 x 10(-7)), but not rs10011796 (OR = 1.06, P = 0.69).
Conclusion. This study has confirmed the significant association of ABCG2 rs2231142 with poor response to allopurinol.

• 出版日期2018-4